Loading
The final results of POLO showed that olaparib did not lengthen overall survival on average, although about twice as many patients on olaparib were alive at three years, and the drug delayed the time until a second treatment was needed.
Prespecified final overall survival analysis of the POLO trial (154 patients with a germline BRCA mutation and platinum-sensitive metastatic pancreatic cancer). Median overall survival was 19.0 months with olaparib and 19.2 months with placebo (hazard ratio 0.83, not significant).
Survival curves separated late: about 34 percent of olaparib patients were alive at three years against about 18 percent on placebo. Time to second disease progression and time to second subsequent therapy favoured olaparib, and no new safety signals appeared with longer follow-up.
Olaparib maintenance remains a standard option because of its progression-free benefit, tolerability and long-term survivors, but patients should know that it has not been shown to extend average survival.
Shares Hedy L. Kindler, Talia Golan, POLO, Germline BRCA1/2 pathogenic variant (gBRCAm).
Shares Talia Golan, POLO, Germline BRCA1/2 pathogenic variant (gBRCAm), Germline BRCA mutation (gBRCA).
Shares Germline BRCA1/2 pathogenic variant (gBRCAm), Germline BRCA mutation (gBRCA), BRCA or PALB2-mutant pancreatic ductal adenocarcinoma, BRCA1 / BRCA2 (HRD).
Shares Germline BRCA1/2 pathogenic variant (gBRCAm), Germline BRCA mutation (gBRCA), Olaparib, BRCA1 / BRCA2 (HRD).
Shares POLO, Germline BRCA mutation (gBRCA), Olaparib, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question.
Shares Talia Golan, POLO, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma.
Shares Germline BRCA1/2 pathogenic variant (gBRCAm), Germline BRCA mutation (gBRCA), BRCA or PALB2-mutant pancreatic ductal adenocarcinoma, BRCA1 / BRCA2 (HRD).
Shares Germline BRCA1/2 pathogenic variant (gBRCAm), Germline BRCA mutation (gBRCA), BRCA1 / BRCA2 (HRD), Journal of Clinical Oncology.